Objective: Emotional dysregulation and irritability are common in individuals with autism spectrum disorder (ASD). We conducted the first meta-analysis assessing the efficacy of a broad range of pharmacological interventions for emotional dysregulation and irritability in ASD and predictors of response.
Method: Following a preregistered protocol (PROSPERO: CRD42021235779), we systematically searched multiple databases until January 1, 2021. We included placebo-controlled randomized controlled trials (RCTs) and evaluated the efficacy of pharmacological interventions and predictors of response for emotional dysregulation and irritability. We assessed heterogeneity using Q statistics and publication bias. We conducted subanalyses and meta-regressions to identify predictors of response. The primary effect size was the standardized mean difference. Quality of studies was assessed using the Cochrane Risk of Bias Tool (RoB2).
Results: A total of 2,856 individuals with ASD in 45 studies were included, among which 26.7% of RCTs had a high risk of bias. Compared to placebo, antipsychotics (standardized mean difference = 1.028, 95% CI = 0.824-1.232) and medications used to treat attention-deficit/hyperactivity disorder (ADHD) (0.471, 0.061-0.881) were significantly better than placebo in improving emotional dysregulation and irritability, whereas evidence of efficacy was not found for other drug classes (p > .05). Within individual medications, evidence of efficacy was found for aripiprazole (1.179, 0.838-1.520) and risperidone (1.074, 0.818-1.331). Increased rates of comorbid epilepsy (β = -0.049, p = .026) were associated with a lower efficacy.
Conclusion: Some pharmacological interventions (particularly risperidone and aripiprazole) have proved efficacy for short-term treatment of emotional dysregulation and irritability in ASD and should be considered within a multimodal treatment plan, taking into account also the tolerability profile and families' preferences.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaac.2022.03.033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adolescent Impulsivity and Emotion Dysregulation: The Moderating Role of Parental Socialization of Negative Emotions.
Psychol Rep
January 2025
Department of Clinical Psychology, Seattle Pacific University, Seattle, WA, USA.
This study investigated whether parental socialization of negative emotions moderated the relationship between adolescents' low executive function or high impulsivity and their current or subsequent emotion dysregulation. Emotion dysregulation, characterized by difficulties in managing the intensity and duration of emotions, is a transdiagnostic factor linked to adverse outcomes. Youth with poor executive functioning and/or high impulsivity are at risk for emotion dysregulation; however, the role of parenting in influencing this trajectory warrants exploration.
View Article and Find Full Text PDFNeural regulation of pain anticipation is associated with mindful behavior change in patients with anxiety or depression: A pilot study.
Psychiatry Res Neuroimaging
December 2024
Center for Mindfulness and Compassion, Cambridge Health Alliance, Cambridge, MA, USA; Harvard Medical School, Boston, USA.
Behavior change often requires overcoming discomfort or difficult emotions. Emotional dysregulation associated with anxiety or depression may prevent behavior change initiation among people managing chronic illness. Mindfulness training may catalyze chronic disease self-management by reducing experiential avoidance of aversive experiences that act as barriers to change initiation.
View Article and Find Full Text PDFClassification of Irritable Bowel Syndrome Using Brain Functional Connectivity Strength and Machine Learning.
Neurogastroenterol Motil
January 2025
School of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Background: Irritable Bowel Syndrome (IBS) is a prevalent condition characterized by dysregulated brain-gut interactions. Despite its widespread impact, the brain mechanism of IBS remains incompletely understood, and there is a lack of objective diagnostic criteria and biomarkers. This study aims to investigate brain network alterations in IBS patients using the functional connectivity strength (FCS) method and to develop a support vector machine (SVM) classifier for distinguishing IBS patients from healthy controls (HCs).
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
Background: Apathy may appear as a less acute late-life syndrome; however, it is associated with accelerated progression to dementia and contributes to adverse outcomes for patients and caregivers. These findings are not surprising since apathy can cause individuals to forego activities that improve cardiovascular and cognitive health (e.g.
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Background: The Visual Cognitive Assessment Test (VCAT) is a visual based, language neutral cognitive assessment validated across cultures and ethnicities, that allows for early diagnosis of cognitive impairment. The VCAT assess domains of cognition - Memory, Visuospatial function, attention, language and Executive function. The Mild Behavioural Impairment Checklist (MBI-C) was developed to assess five domains of NPS - Decreased motivation, emotional dysregulation, impulse control, social inappropriateness and abnormal beliefs/perceptions Current research indicates an association between MBI symptom severity and poorer cognitive performance in the domains of memory.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!